TAPI-0

CAT: 0804-HY-118694-01Size: 1 mgDry Ice: NoHazardous: No
CAT#: HY-118694-01Size: 1 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF-α processing[1][2].
CAS Number
[163958-73-4]
UNSPSC
12352209
Hazard Statement
H301
Target
Bacterial; MMP; TNF Receptor
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/tapi-0.html
Purity
98.98
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
ONC(C[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)CC1=CC2=C(C=C1)C=CC=C2)=O)CC(C)C)=O
Molecular Formula
C24H32N4O5
Molecular Weight
456.53
Precautions
H301
References & Citations
[1]Amit Balakrishnan, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006 Jun 16;281 (24) :16691-9.|[2]Shiori Haga, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85 (3) :551-5.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported